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Disclosure of Resident Involvement in Ophthalmic Surgery
A n important objective of ophthalmic graduate medical education (GME) is to provide sufficient surgical training to ophthalmology residents so they are competent to enter comprehensive ophthalmic practice. This objective, however, must be balanced with a commitment to provide high-quality patient care, which includes respecting patients' preferences to be informed about the degree of resident involvement in their eye surgery. [1] [2] [3] [4] Currently, the prevalence and details of disclosure policies regarding resident participation and barriers to their implementation in US ophthalmology GME programs are unknown. To help benchmark current practices and assist programs in formulating strategies to implement full disclosure policies, we surveyed US ophthalmology GME program directors (PDs) to determine current practices and policies regarding disclosure of resident involvement in ophthalmic surgery.
Methods. After receiving a study exemption from the Providence VA Medical Center Institutional Review Board, the FREIDA online database (http://www.ama-assn.org /go/freida) was used to identify all ophthalmology GME programs accredited by the Accreditation Council for Graduate Medical Education. Each facility was called to verify the PD's contact information. An anonymous survey including multiple-choice and Likert-style questions ( Table 1 and Table 2 ) was created at http://www .surveymonkey.com. The survey link was sent to all US ophthalmology GME PDs.
Results.
One hundred seventeen PDs were surveyed; results are summarized in Table 1 and Table 2 Comment. This study suggests that a minority of US ophthalmology GME programs have an established resident disclosure policy. Also, the presence or absence of a policy may affect who PDs believe should have the primary responsibility to inform patients about trainee involvement in their ophthalmic surgery: only half the PDs in programs with policies indicated that the attending has the primary responsibility, whereas most PDs in programs without policies believe that the attending should have the primary responsibility. In addition, the potential loss of resident surgical cases, the lack of guidance from ophthalmological societies, and perceived patient anxiety may be more important barriers to disclosure than medicolegal risk or lack of time.
The study has several limitations. First, the survey response rate of 45.3% may limit the generalizability of the results; however, this rate is comparable to the response rates of 32% and 48% in 2 recent surveys of US ophthalmology PDs. 5, 6 Second, the multiple-choice format of the survey may have caused bias and prevented us from uncovering other potential barriers to disclosure. Third, we did not investigate how a resident's role in a program-eg, as a primary caregiver in a county hospital vs an assistant physician in a faculty practice-may have affected the divergence in PD attitudes on resident disclosure. This study underscores the need for further research to determine how a formal disclosure policy affects the degree to which patients at teaching hospitals are informed about resident participation in their ophthalmic surgery and how different disclosure policies affect patient consent for resident participation and resident surgical training opportunities. Abbreviation: ACGME, Accreditation Council for Graduate Medical Education. a Response choices were strongly disagree, disagree, neither agree nor disagree, agree, and strongly agree.
Intravitreal Bevacizumab in Advanced-Stage Neovascular Age-Related Macular Degeneration With Visual Acuity Lower Than 20/200
A lthough intravitreal anti-vascular endothelial growth factor has greatly improved the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration, [1] [2] [3] [4] little is known regarding the effects in more advanced stages associated with low visual acuity. We designed a randomized clinical trial to address this subject.
Methods.
The randomized clinical trial compared the effects of the intravitreal bevacizumab injection (1.25 mg) vs observation for age-related macular degenerationrelated naive subfoveal CNV with best-corrected visual acuity (BCVA) lower than 20/200, with follow-up for 6 months. After institutional review board approval, the study was registered at http://www.clinicaltrials.gov /(NCT01327222). Inclusion criteria were the following: naive subfoveal CNV, BCVA lower than 20/200 on the Early Treatment Diabetic Retinopathy Study chart, and activity documented by fluorescein leakage and fluid on optical coherence tomography. We excluded patients with retinal or subretinal hemorrhage or subretinal fibrosis greater than 50% of the lesion, recent intraocular surgery, other ocular disease, or severe cardiovascular disorders. Sequentially numbered envelopes were used to randomize patients. Each patient contributed 1 study eye and underwent a complete ophthalmologic examination, including the National Eye Institute 25-item Visual Function Questionnaire and bestcorrected visual acuity at baseline and at the final visit.
Fluorescein angiography and optical coherence tomography results were independently read and intravitreal bevacizumab injection was performed by 2 masked investigators (A.P. and D.S.K.). After the loading phase with 3 monthly consecutive injections, re-treatments were administered on a pro re nata basis if monthly examinations by a masked examiner revealed subretinal or intraretinal fluid, fluorescein leakage, or new hemorrhages.
Primary outcome measures were changes in the mean BCVA and proportion of eyes improving by more than 1 and more than 3 lines at the 6-month examination. Secondary outcome measures included changes in the mean central macular thickness and National Eye Institute 25-item Visual Function Questionnaire score. We used t test for statistical analyses. P Ͻ .05 was considered statistically significant.
The study was designed to detect a 10-letter difference (SD 1 line) on the Early Treatment Diabetic Retinopathy Study chart. About 6 eyes in each arm are required to detect this difference (90% power, 2-sided 5% significance level).
Results. Twenty-one of 28 patients were recruited, with 7 excluded owing to cataract. The mean (SD) age was 71.5 (4.2) years, and 13 of the recruited patients were female. The mean (SD) symptom duration was 23.3 (4.0) months. Among the 21 patients, 11 and 10 were ran- 
